FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

McKesson Gemcitabine Injection Recall

Gemcitabine Injection, 1 g per 26

McKesson · Irving, TX

Risk level
Class II
Reported by FDA
Jul 8, 2026
Recall ID
D-0714-2026
Check your lot numberHow we source this data

Summary

McKesson recalled Gemcitabine Injection starting Jun 10, 2026. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0714-2026 on Jul 8, 2026. Reason: Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment. Status: Ongoing.

Why it was recalled

Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.

Product description

Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01

Lot numbers, UPCs & expiration codes

Lot #: CB0046, Exp. Date 06/2027

Where it was sold

Nationwide within the United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0714-2026
Classification
Class II
Status
Ongoing
Recall initiated
Jun 10, 2026
FDA report date
Jul 8, 2026
Quantity
74 units
Recall type
Voluntary: Firm initiated
Recalling firm
McKesson

Original FDA data

Every field from FDA enforcement report D-0714-2026, exactly as published.

Show all FDA fields
City
Irving
State
TX
Status
Ongoing
Country
United States
Event ID
99262
Address
6555 State Highway 161
Code information
Lot #: CB0046, Exp. Date 06/2027
Postal code
75039-2402
Report date
Jul 8, 2026
Product type
Drugs
Recall number
D-0714-2026
Classification
Class II
Recalling firm
McKesson
Product quantity
74 units
Reason for recall
Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01
Distribution pattern
Nationwide within the United States
Recall initiation date
Jun 10, 2026
Initial firm notification
Telephone
Center classification date
Jul 21, 2026

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0714-2026, published Jul 8, 2026. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls